Rafferty Asset Management
CERE

Rafferty Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Rafferty Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-183,293
Closed -$7.49M – 1203
2024
Q2 		$7.49M Sell
183,293
-39,021
-18% -$1.62M 0.03% 329
2024
Q1 		$9.4M Buy
222,314
+80,837
+57% +$3.4M 0.04% 285
2023
Q4 		$6M Sell
141,477
-57,516
-29% -$1.65M 0.03% 400
2023
Q3 		$4.34M Buy
198,993
+22,288
+13% +$558K 0.03% 419
2023
Q2 		$5.62M Sell
176,705
-33,480
-16% -$1.03M 0.03% 382
2023
Q1 		$5.13M Sell
210,185
-28,470
-12% -$836K 0.03% 379
2022
Q4 		$7.53M Buy
238,655
+87,413
+58% +$2.47M 0.06% 279
2022
Q3 		$4.27M Buy
151,242
+77,264
+104% +$2.3M 0.05% 364
2022
Q2 		$1.96M Sell
73,978
-39,021
-35% -$1.11M 0.02% 469
2022
Q1 		$3.96M Sell
112,999
-22,198
-16% -$648K 0.02% 433
2021
Q4 		$4.38M Buy
135,197
+53,303
+65% +$1.88M 0.02% 434
2021
Q3 		$2.42M Buy
81,894
+40,059
+96% +$1.12M 0.02% 582
2021
Q2 		$1.07M Sell
41,835
-19,750
-32% -$283K 0.01% 865
2021
Q1 		$846K Buy
+61,585
New +$901K 0.01% 813

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Rafferty Asset Management's CERE Position: Q3 2024 in Review

Rafferty Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 183,293 shares — an estimated $7.49M sold.

Rafferty Asset Management first reported a position in CERE in Q1 2021 and held it in 14 quarters. The position peaked at $9.4M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Rafferty Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 183,293 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.49M.
  • Rafferty Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
  • Rafferty Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $9.4M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.